Philip Barach
Vorstandsvorsitzender bei Équilibre BioPharmaceuticals Corp.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Steven N. Gordon | M | 56 |
Équilibre BioPharmaceuticals Corp.
 Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
| Francois Maisonrouge | M | - |
Équilibre BioPharmaceuticals Corp.
Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
| Peter Simon | M | 75 |
Équilibre BioPharmaceuticals Corp.
Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
| David Freidman | M | - |
Équilibre BioPharmaceuticals Corp.
Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
| Steven N. Gordon | M | - |
Équilibre BioPharmaceuticals Corp.
Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
| Christina M. Ramirez | M | - |
Équilibre BioPharmaceuticals Corp.
Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Philip Barach
- Persönliches Netzwerk
